Liothyronine Sodium Tablet
NDC Package 87063-080-01
Package Information
Liothyronine Sodium tablets is liothyronine is used to treat an underactive thyroid (hypothyroidism). This formulation utilizes a tablet delivery system. Marketed by Asclemed Usa Inc., this product is identified by NDC 87063-080 and is authorized under FDA application ANDA200295.
Identification & Billing
- RxCUI: 903456 - liothyronine sodium 5 MCG Oral Tablet
- RxCUI: 903456 - liothyronine sodium 0.005 MG Oral Tablet
- RxCUI: 903697 - liothyronine sodium 25 MCG Oral Tablet
- RxCUI: 903697 - liothyronine sodium 0.025 MG Oral Tablet
- RxCUI: 903703 - liothyronine sodium 50 MCG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 87063 - Asclemed Usa Inc.
- 87063-080 - Liothyronine Sodium
- 87063-080-01 - 100 TABLET in 1 BOTTLE
- 87063-080 - Liothyronine Sodium
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (87063-080). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 87063-080-01 identifies a specific commercial package of 100 tablet in 1 bottle of Liothyronine Sodium, a human prescription drug labeled by Asclemed Usa Inc.. This tablet is formulated for oral use and contains liothyronine sodium as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Asclemed Usa Inc. on December 03, 2012. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
Liothyronine is used to treat an underactive thyroid (hypothyroidism). It replaces or provides more thyroid hormone, which is normally made by the thyroid gland. Liothyronine is a man-made form of thyroid hormone. Low thyroid hormone levels can occur naturally or when the thyroid gland is injured by radiation/medications or removed by surgery. Having enough thyroid hormone helps you stay healthy. For children, having enough thyroid hormone helps them grow and learn normally. This medication is also used to treat other types of thyroid problems (such as certain types of goiters, thyroid cancer). It can also be used to test for certain types of thyroid disease. This medication should not be used to treat infertility unless it is caused by low thyroid hormone levels.
How is this Asclemed Usa Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 87063008001. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.